Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 4;16(9):313.
doi: 10.3390/md16090313.

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

Giulia Prinzi  1 , Alessia Santoro  2 , Palma Lamonaca  3 , Vittorio Cardaci  4 , Massimo Fini  5 , Patrizia Russo  6
Affiliations
Review

Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds

Giulia Prinzi et al. Mar Drugs. .

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by long-term airflow limitation. Early-onset COPD in non-smoker subjects is ≥60 years and in the elderly is often associated with different comorbidities. Cognitive impairment is one of the most common feature in patients with COPD, and is associated with COPD severity and comorbidities. Cognitive impairment in COPD enhances the assistance requirement in different aspects of daily living, treatment adherence, and effectual self-management.This review describes various bioactive compounds of natural marine sources that modulate different targets shared by both COPD and cognitive impairment and hypothesizes a possible link between these two syndromes.

Keywords: COPD; cognitive impairment; management strategy; marine bioactive compound; systems approaches.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Fucoxanthin.
Figure 2
Figure 2
Austrasulfone.
Figure 3
Figure 3
TMC-256C1.
Figure 4
Figure 4
1-O-(Myristoyl) glycerol.
Figure 5
Figure 5
Sargaquinoic acid.
Figure 6
Figure 6
Bafilomycin.
Figure 7
Figure 7
Coibamide A.
Figure 8
Figure 8
Manzamine A.
Figure 9
Figure 9
Papuamine.
Figure 10
Figure 10
Apo-9′-fucoxanthinone.
Figure 11
Figure 11
Omega-3 fatty acids. (a) Alpha-linolenic acid. (b) Docosahexaenoic acid. (c) Eicosapentaenoic acid.
Figure 12
Figure 12
Phosphatidylcholine (a) and gracilin (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. [(accessed on 4 July 2018)]; Available online: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prev....
    1. Vanfleteren L.E., Spruit M.A., Wouters E.F., Franssen F.M. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir. Med. 2016;4:911–924. doi: 10.1016/S2213-2600(16)00097-7. - DOI - PubMed
    1. Soriano J.B., Abajobir A.A., Abate K.H., Abera S.F., Agrawal A., Ahmed M.B., Aichour A.N., Aichour I., Aichour M.T.E., Alam K., et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir. Med. 2017;5:691–706. doi: 10.1016/S2213-2600(17)30293-X. - DOI - PMC - PubMed
    1. Agustí A., Faner R. COPD beyond smoking: New paradigm, novel opportunities. Lancet Respir. Med. 2018;6:324–326. doi: 10.1016/S2213-2600(18)30060-2. - DOI - PubMed
    1. Stoller J.K., Lacbawan F.L., Aboussouan L.S. Alpha-1 Antitrypsin Deficiency. In: Adam M.P., Ardinger H.H., Pagon R.A., Wallace S.E., Bean L.J.H., Stephens K., Amemiya A., editors. GeneReviews®. University of Washington; Seattle, WA, USA: 2006. - PubMed

MeSH terms